Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Provenge and Bevacizumab in Progressive Prostate Cancer
NCT00027599Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2001
- Primary completion
- Jul 2007
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sipuleucel-T and bevacizumab in prostate cancer (PCa), sponsored by National Cancer Institute. Primary endpoints: Decline in prostate-specific antigen (PSA) value, Effect on PSA doubling time and 2 more. Started Dec 2001; status: completed.
02
Drugs
sipuleucel-Tbevacizumab
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00027599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00027599.